1. G1‐S transition defects occur in most breast cancers and predict outcome

   • Niels Hilmer Nielsen
   • Martin Lodén
   • Göran Landberg

   OriginalPaper Pages: 103 - 110

2. Postoperative chemo–endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor–positive stage II breast cancer

   • Keizo Sugimachi
   • Yoshihiko Maehara
   • Yasumasa Monden

   OriginalPaper Pages: 111 - 122

3. Three new active cisplatin‐containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial

   • Giorgio Cocconi
   • Giancarlo Bisagni
   • Luisa Savoldi

   OriginalPaper Pages: 123 - 130

4. Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

   • S. Pyrhönen
   • J. Ellmén
   • D.F. Hayes

   OriginalPaper Pages: 131 - 141

5. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade

   • Walter Tschugguel
   • Christian Schneeberger
   • Johannes C. Huber

   OriginalPaper Pages: 143 - 149

6. Overexpression of basic fibroblast growth factor (FGF–2) downregulates Bcl–2 and promotes apoptosis in MCF–7 human breast cancer cells

   • Paul Maloof
   • Qin Wang
   • Robert Wieder

   OriginalPaper Pages: 151 - 165

7. Immunohistochemical labelling for prostate–specific antigen in breast carcinomas

   • Kalle A. Alanen
   • Teijo Kuopio
   • Timo J. Nevalainen

   OriginalPaper Pages: 167 - 174

8. PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells

   • Julius Leyton
   • Yehoshua Gozes
   • Terry W. Moody

   OriginalPaper Pages: 175 - 184

9. Hsp27 overexpression inhibits doxorubicin–induced apoptosis in human breast cancer cells

   • Rhonda K. Hansen
   • Irma Parra
   • Suzanne A. W. Fuqua

   OriginalPaper Pages: 185 - 194